TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
LobSor Pharmaceuticals AB
Closing information (x1000 NOK)
| Closing information | 2025/12 | 2024/12 | 2023/12 |
| Turnover |
124,664
|
87,519 | |
| Financial expenses |
273,625
|
0 | |
| Earnings before taxes |
-175,704
|
80,191 | |
| EBITDA |
214,608
|
77,335 | |
| Total assets |
1,976,961
|
188,831 | |
| Current assets |
121,946
|
156,795 | |
| Current liabilities |
461,065
|
92,454 | |
| Equity capital |
180,196
|
96,377 | |
| - share capital |
47
|
45 | |
| Employees (average) |
3
|
3
|
3 |
Financial ratios
| Fiscal year | 2025/12 | 2024/12 | 2023/12 |
| Solvency |
9.1%
|
51.0% | |
| Turnover per employee |
41,555
|
29,173 | |
| Profit as a percentage of turnover |
-140.9%
|
91.6% | |
| Return on assets (ROA) |
5.0%
|
42.5% | |
| Current ratio |
26.4%
|
169.6% | |
| Return on equity (ROE) |
-97.5%
|
83.2% | |
| Change turnover |
35,567
|
74,891 | |
| Change turnover % |
14%
|
40%
|
593% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
0%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2025/12 | 2024/12 | 2023/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.